MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Biological: MEDI-563

First Posted Date: 2007-08-07

Last Posted Date: 2008-11-27

Lead Sponsor: MedImmune LLC

Target Recruit Count: 42

Registration Number: NCT00512486

Locations: 🇺🇸
Northeast Medical Research Associates, Inc., North Darthmouth, Massachusetts, United States
🇺🇸
Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸
Allergy-Asthma-K4, Madison, Wisconsin, United States

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Phase 1

Terminated

Conditions: Healthy

Interventions: Biological: MEDI-560
Biological: Placebo

First Posted Date: 2007-07-30

Last Posted Date: 2011-12-30

Lead Sponsor: MedImmune LLC

Target Recruit Count: 30

Registration Number: NCT00508651

Locations: 🇺🇸
Children's Investigational Research Program, Bentonville, Arkansas, United States
🇺🇸
Arkansas Pediatric Clinic, Little Rock, Arkansas, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States

and more 20 locations

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: MEDI528 0.3 mg/kg
Biological: MEDI528 1 mg/kg
Biological: MEDI528 3 mg/kg
Other: PLACEBO

First Posted Date: 2007-07-25

Last Posted Date: 2013-12-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 36

Registration Number: NCT00507130

Locations: 🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦
Hopital Laval, Quebec, Canada

and more 6 locations

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Phase 1

Completed

Conditions: Respiratory Viral Infections
Respiratory Syncytial Virus Infections
Parainfluenza Virus 3, Human

Interventions: Biological: MEDI-534

First Posted Date: 2007-06-28

Last Posted Date: 2012-07-19

Lead Sponsor: MedImmune LLC

Target Recruit Count: 49

Registration Number: NCT00493285

Locations: 🇺🇸
North Georgia Clinical Research Center, Dalton, Georgia, United States
🇺🇸
Withrop University Hospital, Mineola, New York, United States
🇺🇸
Craig A. Spiegel, MD, Bridgeton, Missouri, United States

and more 27 locations

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Lupus

Interventions: Biological: MEDI 545
Other: Placebo

First Posted Date: 2007-06-06

Last Posted Date: 2012-07-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 183

Registration Number: NCT00482989

Locations: 🇨🇱
Research Site, Santiago, Chile

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Phase 2

Terminated

Conditions: Asthma

Interventions: Other: PLACEBO
Biological: MEDI528 9 mg/kg

First Posted Date: 2007-06-06

Last Posted Date: 2014-03-07

Lead Sponsor: MedImmune LLC

Target Recruit Count: 11

Registration Number: NCT00483041

Locations: 🇺🇸
Washington Univeristy School of Medicine, Division of Pulmonary and Critical Care Medicine, St. Louis, Missouri, United States
🇺🇸
Wake Forest University, Baptist Medicial Center, Winston-Salem, North Carolina, United States
🇺🇸
Brigham & Women's Hospital Asthma Research, Boston, Massachusetts, United States

and more 1 locations

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: Frozen FluMist®
Other: Placebo

First Posted Date: 2007-05-30

Last Posted Date: 2008-12-22

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00480155

Locations: 🇺🇸
Covance Portland, Portland, Oregon, United States
🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
🇺🇸
Covance Austin CRU, Austin, Texas, United States

A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545

Phase 1

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Biological: MEDI 545
Other: Placebo

First Posted Date: 2007-05-14

Last Posted Date: 2011-11-17

Lead Sponsor: MedImmune LLC

Target Recruit Count: 40

Registration Number: NCT00472758

Locations: 🇨🇦
Innovaderm Research, Inc., Montreal, Canada
🇨🇦
Probity Medical Research, Waterloo- Ontario, Canada
🇨🇦
Innovaderm Research, Laval, Inc., Laval-Quebec, Canada

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Phase 2

Completed

Conditions: Influenza Vaccine

Interventions: Biological: FluMist, Influenza Virus Vaccine Live
Biological: TIV, Trivalent Inactivated Influenza Virus Vaccine

First Posted Date: 2007-04-18

Last Posted Date: 2021-10-06

Lead Sponsor: MedImmune LLC

Target Recruit Count: 101

Registration Number: NCT00461981

Locations: 🇺🇸
Harvey Pediatrics, Jonesboro, Arkansas, United States
🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States

and more 16 locations

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Phase 2

Terminated

Conditions: Participants Less Than 12 Months of Age With RSV Illness

Interventions: Biological: Motavizumab
Other: Placebo

First Posted Date: 2007-02-14

Last Posted Date: 2021-08-17

Lead Sponsor: MedImmune LLC

Target Recruit Count: 12

Registration Number: NCT00435227

Locations: 🇺🇸
Research Site, Morgantown, West Virginia, United States
🇺🇸
West Virginia University Pediactric Center, Charleston, West Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy